{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:22:16Z","timestamp":1773415336992,"version":"3.50.1"},"reference-count":121,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1080\/14712598.2026.2634055","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:05:51Z","timestamp":1771823151000},"page":"109-123","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed\/refractory disease and future directions"],"prefix":"10.1080","volume":"26","author":[{"given":"Elena","family":"Bayly-McCredie","sequence":"first","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]},{"name":"The University of Melbourne","place":["Melbourne, Australia"]},{"name":"Monash University","place":["Melbourne, Australia"]},{"name":"Sir Peter MacCallum Cancer Centre","place":["Melbourne, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costas Kleanthes","family":"Yannakou","sequence":"additional","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]},{"name":"The University of Melbourne","place":["Melbourne, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Fiorenza","sequence":"additional","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]},{"name":"Alfred Health","place":["Melbourne, Australia"]},{"name":"University of Sydney","place":["Camperdown, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Wisniowski","sequence":"additional","affiliation":[{"name":"Epworth HealthCare","place":["East Melbourne, Australia"]},{"name":"Eastern Health Box Hill","place":["Box Hill, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae321"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02753-x"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01697-0"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724411"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2353751"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074"},{"key":"e_1_3_5_14_1","unstructured":"U. S. Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. 2023 [cited 2025 Jun 24]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166854"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162738"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7504"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210520"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7577"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7576"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.383.383"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0007"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0121"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14121"},{"key":"e_1_3_5_28_1","unstructured":"U. S. Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. 2022 [cited 2025 Jun 28]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_5_29_1","unstructured":"U. S. Food and Drug Administration. FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma. 2025 [cited 2025 Aug 6]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002736"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180127"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.002"},{"key":"e_1_3_5_33_1","unstructured":"Study of CC-93269 a BCMA x CD3 T cell engaging antibody in participants with relapsed and refractory multiple myeloma [Internet]. 2025 [cited 2025 Aug 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03486067"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT013"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178948"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2357274"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.388"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118425"},{"key":"e_1_3_5_39_1","unstructured":"BCMA bispecific antibody therapy for post-BCMA CAR T-Cell therapy relapse (RECLAIM) [Internet]. 2025 [cited 2025 Aug 6]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT07009899?term=LINVOSELTAMAB&rank=5"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7527"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1304365"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1424925"},{"key":"e_1_3_5_43_1","unstructured":"Study assessing activity of intravenous (IV) etentamig monotherapy versus standard available therapies in adult participants with relapsed or refractory multiple myeloma (CERVINO) [Internet]. 2025 [cited 2025 Aug 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06158841"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002393"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0337-y"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.04.008"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7522"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-4058"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-100"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205872"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000435"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2247"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0124"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8040"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0539-0"},{"key":"e_1_3_5_59_1","unstructured":"A study to determine the recommended dose and schedule and evaluate the safety and preliminary efficacy of mezigdomide in combination with elranatamab in participants with relapsed and\/or refractory multiple myeloma [Internet]. 2025 [cited 2025 Jul 13]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06988488?term=AREA%5BExpandedAccessNCTId%5DNCT06994117&rank=1"},{"key":"e_1_3_5_60_1","unstructured":"A study evaluating the safety pharmacokinetics and activity of the combination of cevostamab and elranatamab in participants with relapsed or refractory multiple myeloma (R\/R MM) [Internet]. 2025 [cited 2025 Jul 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05927571"},{"key":"e_1_3_5_61_1","unstructured":"Phase II trials of letermovir prophylaxis in patients with RRMM undergoing elranatamab therapy (OPTIMUS-EL) [Internet]. 2025 [cited 2025 Jul 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06920251"},{"key":"e_1_3_5_62_1","unstructured":"Outpatient and intermittent dosing of elranatamab in relapsed\/refractory multiple myeloma (EMBRACE) [Internet]. 2025 [cited 2025 Jul 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06421675"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2253"},{"key":"e_1_3_5_64_1","unstructured":"Use of elranatamab in patients with high-risk smoldering multiple myeloma (ERASMM) [Internet]. 2024 [cited 2025 Jul 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06183489"},{"key":"e_1_3_5_65_1","unstructured":"Elranatamab post Cilta-cel in patients with clinical high risk relapsed myeloma [Internet]. 2025 [cited 2025 Jul 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06947083"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2448898"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1582975"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205481"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01200-w"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-4588"},{"key":"e_1_3_5_71_1","volume-title":"Presented at: EHA Congress 2025","author":"Tomkins O","year":"2025","unstructured":"Tomkins O, Feixas Tenorio P, Willis F, et al. (PF796) single agent elranatamab for relapsed\/refractory multiple myeloma (R\/R MM) \u2013 multi-centre real-world outcomes from 5 United Kingdom (UK) sites [poster]. In: Presented at: EHA Congress 2025; Madrid, Spain. Available from 2025 Jun 13. Available from: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4160203\/oliver.tomkins.single.agent.elranatamab.for.relapsed.refractory.multiple.html"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-136"},{"key":"e_1_3_5_73_1","unstructured":"European Medicines Agency. An international non-interventional post-authorization safety study to evaluate the effectiveness and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) treated in real-world settings (MagnetisMM-16). Internet. 2023 [cited 2025 Dec 6]. Available from: https:\/\/catalogues.ema.europa.eu\/node\/3798\/administrative-details"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-4045"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae068"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181951"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2269"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8045"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061360"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.217"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198117"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026212"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012354"},{"key":"e_1_3_5_85_1","unstructured":"European Medicines Agency. Elrexfio. 2025 [cited 2025 Sep 13]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elrexfio"},{"key":"e_1_3_5_86_1","unstructured":"Therapeutic Goods Administration. Elrexfio (elranatamab). 2024 [cited 2025 Sep 13]. Available from: https:\/\/www.tga.gov.au\/resources\/auspmd\/elrexfio-elranatamab"},{"key":"e_1_3_5_87_1","unstructured":"Medicines & Healthcare products Regulatory Agency. Elranatamab. 2023 [cited 2025 Dec 29]. Available from: https:\/\/products.mhra.gov.uk\/search\/?search=elranatamab&page=1&doc=Spc&rerouteType=0"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02531-1"},{"key":"e_1_3_5_89_1","unstructured":"Canada\u2019s Drug Agency. Elranatamab. 2024 [cited 2025 Dec 29]. Available from: https:\/\/www.cda-amc.ca\/elranatamab"},{"key":"e_1_3_5_90_1","unstructured":"Health Sciences Authority. New drug approvals \u2013 December 2024. 2025 [cited 2025 Dec 29]. Available from: https:\/\/www.hsa.gov.sg\/announcements\/new-drug-approval\/new-drug-approvals\u2014december-2024"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2025.07.018"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_5_93_1","unstructured":"U. S. Food and Drug Administration. Biologic licence application (BLA): 761345. 2025 [cited 2025 Dec 12]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00361-3"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-7936"},{"key":"e_1_3_5_96_1","volume-title":"Proceedings from an International Myeloma Society 21st annual meeting oral abstract. Clin Lymphoma Myeloma Leuk","author":"Scott SA","year":"2025","unstructured":"Scott SA, Roberts DL, Gupta VA, et al. Feasibility and safety of outpatient model for administration of bispecific antibodies. In: Lonial S, editor. Proceedings from an International Myeloma Society 21st annual meeting oral abstract. Clin Lymphoma Myeloma Leuk; 2025."},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19507"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182388"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.05.011"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187349"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235632"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-4557"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967688.12579.64"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.266841"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203778"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2283"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168903"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028383"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200933"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2634055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:47:40Z","timestamp":1773402460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2634055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1080\/14712598.2026.2634055"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2634055","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}